Abstract
Background: Prostate cancer (PCa) is a highly heterogeneous disease, with cases ranging from indolent to highly aggressive forms. Ongoing research focuses on identifying new biomarkers to improve early risk stratification in PCa, addressing current limitations to accurately evaluate disease progression. A promising new approach to aid PCa risk stratification is digital spatial profiling (DSP) of PCa tissue. Methods: A total of 94 regions of interest from 38 PCa patients at first diagnosis were analyzed for the expression of 44 proteins, including components of the PI3K-AKT, MAPK, and cell death signaling pathways as well as immune cell markers. An additional validation cohort consisting of 154 PCa patients with long-term follow-up data was analyzed using immunohistochemistry (IHC) to assess the consistency of the identified biomarkers across a larger sample set. Results: DSP identified proliferation marker Ki-67 and phospho-c-Jun N-terminal protein kinase (p-JNK), a member of the MAPK signaling pathway, as significantly upregulated proteins in aggressive PCa (Gleason scores 4 and 5) compared to indolent disease (Gleason score 3). The upregulation of p-JNK was confirmed through IHC. High p-JNK expression was associated with a shorter time to biochemical recurrence (log-rank, p=0.1). Conclusion: Our results indicate that p-JNK may contribute to PCa progression and serve as an early biomarker for aggressive PCa stratification. Identifying this biomarker through DSP could be crucial in advancing disease management and addressing the critical unmet need for more targeted therapies in the treatment of aggressive PCa. Further studies are recommended to evaluate the role of p-JNK in PCa progression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was realized through support by the German Federal Ministry for Economic Affairs and Climate Action (funding #01MT21004A) and the Dieter Morszeck Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the University of Heidelberg School of Medicine gave ethical approval of this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
